Regorafenib Combined with BRAF-/MEK-inhibitors for the Treatment of Refractory Melanoma Brain Metastases
Cancers（2024）
Key words
stage IV-M1d melanoma,brain metastases,regorafenib,BRAF/MEK inhibitors,targeted therapy,RAF dimer inhibitor,class II RAF inhibitor
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined